A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread

This is an open-label, single-arm, prospective, multicenter clinical study designed to evaluate the efficacy and safety of envafolimab in combination with lenvatinib for the treatment of patients with clear cell renal cell carcinoma (ccRCC) accompanied by liver metastases. The Department of Urology at Fudan University Shanghai Cancer Center serves as the primary research center.

NCT Number	NCT07256223
Lead Sponsor	Fudan University Collaborators: Huadong Hospital
Conditions	Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis
Enrollment	30 participants
Start Date	2025-12-01
Primary Completion	2027-11-01 (estimated)
Study Completion	2028-05-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-01